Yahoo
KSE - Delayed Quote KRW

GC Biopharma Corp. (006280.KS)

133,900.00 +3,700.00 (+2.84%)
As of 11:53:01 AM GMT+9. Market Open.
View in AlphaSpace Currency in KRW All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
1,963,952,354.33
1,991,279,093.82
1,679,891,941.47
1,626,643,815.82
1,711,312,739.53
Cost of Revenue
1,445,461,638.47
1,437,159,054.89
1,197,959,660.98
1,142,011,052.95
1,129,508,276.27
Gross Profit
518,490,715.86
554,120,038.93
481,932,280.49
484,632,762.87
581,804,463.26
Operating Expense
471,208,464
484,970,182
449,824,933
450,191,593
500,540,797
Operating Income
47,282,251.86
69,149,856.93
32,107,347.49
34,441,169.87
81,263,666.26
Net Non Operating Interest Income Expense
-48,705,486.16
-47,619,234.69
-37,846,236.86
-25,293,186.20
-14,925,690.98
Pretax Income
-58,188,847.91
-35,331,026.42
-41,109,728.85
-27,134,762.73
85,727,859.93
Tax Provision
5,262,432.03
-5,645,866.97
1,527,335.66
-7,326,031.75
16,313,075.34
Net Income Common Stockholders
-49,901,280.04
-4,673,833.01
-26,280,215.15
-26,631,783.14
65,453,133.85
Basic EPS
-4.37k
-410.00
-2.30k
-2.33k
5.74k
Diluted EPS
-4.37k
-410.00
-2.30k
-2.33k
5.74k
Basic Average Shares
11,399.20
11,399.59
11,411.30
11,415.25
11,412.93
Diluted Average Shares
11,399.20
11,399.59
11,411.30
11,415.25
11,412.93
Total Operating Income as Reported
47,277,251.82
69,149,857.15
32,107,347.88
34,436,169.53
81,263,665.84
Rent Expense Supplemental
4,533,000
4,772,000
4,789,000
4,279,000
4,023,000
Total Expenses
1,916,670,102.47
1,922,129,236.89
1,647,784,593.98
1,592,202,645.95
1,630,049,073.27
Net Income from Continuing & Discontinued Operation
-49,901,280.04
-4,673,833.01
-26,280,215.15
-26,631,783.14
65,453,133.85
Normalized Income
18,583,458.71
105,539,228.99
-13,359,429.31
-24,788,013.26
68,790,762.27
Interest Income
2,214,981
2,826,000
3,331,000
3,190,000
3,467,000
Interest Expense
50,920,468
50,297,235
40,439,237
28,483,187
18,392,691
Net Interest Income
-48,705,486.16
-47,619,234.69
-37,846,236.86
-25,293,186.20
-14,925,690.98
EBIT
-7,268,379.91
14,966,208.58
-670,491.85
1,348,424.27
104,120,550.93
EBITDA
78,298,620.09
102,621,208.58
80,363,675.15
77,247,424.27
169,216,550.93
Reconciled Cost of Revenue
1,445,461,638.47
1,437,159,054.89
1,197,959,660.98
1,142,011,052.95
1,129,508,276.27
Reconciled Depreciation
85,567,000
87,655,000
81,034,167
75,899,000
65,096,000
Net Income from Continuing Operation Net Minority Interest
-49,901,280.04
-4,673,833.01
-26,280,215.15
-26,631,783.14
65,453,133.85
Total Unusual Items Excluding Goodwill
-91,312,985
-110,213,062
-17,001,034
-2,525,667
-4,122,000
Total Unusual Items
-91,312,985
-110,213,062
-17,001,034
-2,525,667
-4,122,000
Normalized EBITDA
169,611,605.09
212,834,270.58
97,364,709.15
79,773,091.27
173,338,550.93
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-22,828,246.25
0
-4,080,248.16
-681,897.12
-784,371.58
12/31/2022 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: